Adjuvant Therapy in Stage I and Stage II Epithelial Ovarian Cancer

APPROXIMATELY 20,000 new epithelial ovarian cancers are reported annually in the United States, and about 30 percent of these are apparently localized (Stages I and II according to the classification of the International Federation of Gynecology and Obstetrics [FIGO]) at initial diagnosis.1 The published five-year survival rates for such patients range from 50 to 70 percent for Stage I cancer to only 38 to 60 percent for Stage II.2 , 3 Prognostic factors such as cell type and histologie grade provide only a partial explanation for the widely variable results. Earlier studies have demonstrated the need for thorough surgical staging to define . . . APPROXIMATELY 20,000 new epithelial ovarian cancers are reported annually in the United States, and about 30 percent of these are apparently localized (Stages I and II according to the classification of the International Federation of Gynecology and Obstetrics [FIGO]) at initial diagnosis.1 The published five-year survival rates for such patients range from 50 to 70 percent for Stage I cancer to only 38 to 60 percent for Stage II.2 , 3 Prognostic factors such as cell type and histologie grade provide only a partial explanation for the widely variable results. Earlier studies have demonstrated the need for thorough surgical staging to define . . .